Jasper Therapeutics (NASDAQ:JSPR) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Tuesday morning, Benzinga reports. They currently have a $65.00 price objective on the stock.

Several other equities analysts have also commented on the stock. Evercore ISI reissued an outperform rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. JMP Securities reaffirmed a market outperform rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Friday, September 27th. Stifel Nicolaus began coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They set a buy rating and a $86.00 price target on the stock. Cantor Fitzgerald reaffirmed an overweight rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Finally, Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an outperform rating on the stock in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of $74.86.

Jasper Therapeutics Stock Up 10.3 %

Shares of Jasper Therapeutics stock opened at $18.28 on Tuesday. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The company has a 50-day simple moving average of $18.97 and a two-hundred day simple moving average of $21.59. The stock has a market capitalization of $275.37 million, a price-to-earnings ratio of -3.25 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.12. On average, sell-side analysts anticipate that Jasper Therapeutics will post -4.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently added to or reduced their stakes in JSPR. Rhumbline Advisers bought a new stake in Jasper Therapeutics during the 2nd quarter worth approximately $300,000. Virtu Financial LLC bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $306,000. American Century Companies Inc. grew its holdings in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after acquiring an additional 3,032 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in Jasper Therapeutics during the 1st quarter worth approximately $599,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Jasper Therapeutics in the 2nd quarter worth approximately $740,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.